Lorlatinib (PF-6463922)

Catalog No.S7536

For research use only.

Lorlatinib (PF-6463922) is a potent, dual ALK/ROS1 inhibitor with Ki of <0.02 nM, <0.07 nM, and 0.7 nM for ROS1, ALK (WT), and ALK (L1196M), respectively. PF-06463922 induces apoptosis. Phase 1.

Lorlatinib (PF-6463922) Chemical Structure

CAS No. 1454846-35-5

Selleck's Lorlatinib (PF-6463922) has been cited by 41 publications

Purity & Quality Control

Choose Selective ALK Inhibitors

Other ALK Products

Biological Activity

Description Lorlatinib (PF-6463922) is a potent, dual ALK/ROS1 inhibitor with Ki of <0.02 nM, <0.07 nM, and 0.7 nM for ROS1, ALK (WT), and ALK (L1196M), respectively. PF-06463922 induces apoptosis. Phase 1.
Targets
ROS1 [1]
(Cell-free assay)
ALK [1]
(Cell-free assay)
ALK (L1196M) [1]
(Cell-free assay)
LTK (TYK1) [1]
(Cell-free assay)
FER [1]
(Cell-free assay)
Click to View More Targets
<0.02 nM(Ki) <0.07 nM(Ki) 0.07 nM(Ki) 2.7 nM 3.3 nM
In vitro

PF-06463922 demonstrates significant cell activity against ALK and a large set of ALK clinical mutations with IC50 ranging from 0.2 nM-77 nM. [1] PF-06463922 significantly inhibits cell proliferation and induces cell apoptosis in the HCC78 human NSCLC cells harboring SLC34A2-ROS1 fusions and the BaF3-CD74-ROS1 cells expressing human CD74-ROS1.[2] PF-06463922 also shows potent growth inhibitory activity and induces apoptosis in the NSCLC cells harboring either non-mutant ALK or mutant ALK fusions. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NIH-3T3 MXfGeY5kfGmxbjDhd5NigQ>? Mnf2NUBpeg>? NF7zTlBKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJGYyOTd2TDDteZRidnRiZYjwdoV{e2WmIHnuJI1wfXOnIF7JTE0{XDNiY3XscJMh[XO|ZYPz[YQh[XNicHjvd5Bpdy2DTFugcIV3\WxiYX\0[ZIhOSCqcjDifUB{[W6md3njbEBGVEmVQTygTWM2OCB;IECuNFAxOiEQvF2u MoDqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6MUmxNVYoRjJ2OEG5NVE3RC:jPh?=
NIH/3T3 M33kRWZ2dmO2aX;uJIF{e2G7 NGP2OGtKdmirYnn0bY9vKG:oIIfpcIQhfHmyZTDFUWw1N0GOSzDGNVE4PExibYX0ZY51KCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIF7JTE8{XDNiY3XscJMtKEmFNUCgQUAxNjByMEKg{txONg>? M1rSRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEOxN|QxLz5{OESzNVM1ODxxYU6=
BAF3 M3Pad2FvfGmycn;sbYZmemG2aY\lJIF{e2G7 MYi3NkBpenN? MWHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDRkOgZ4VtdHNiaHHyZo9zcW6pIFPEO|QuWk:VMTDh[pRmeiB5MjDodpMh[nliU2LCJI9zKEOFS{igZZN{[XluIFnDOVAhRSByLkCwNVIh|ryPLh?= NFjWN|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUK4PFk1OCd-MkmyPFg6PDB:L3G+
NIH-3T3 NIS3OldHfW6ldHnvckBie3OjeR?= MoH1NUBpeg>? MXrJcohq[mm2aX;uJI9nKHerbHSgeJlx\SCqdX3hckBGVUx2LX\1d4VlKEGOSzDlfJBz\XO|ZXSgbY4hdW:3c3WgUmlJNTOWMzDj[YxteyCjc4Pld5Nm\CCjczDwbI9{eGixconsZZRm\CCDTFugcIV3\WxiYX\0[ZIhOSCqcjDifUB{[W6md3njbEBGVEmVQTygTWM2OCB;IECuNFAyOyEQvF2u NGjWOpI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEixPVEyPid-MkS4NVkyOTZ:L3G+
NIH/3T3 M2mzd2Z2dmO2aX;uJIF{e2G7 M4DkR2lvcGmkaYTpc44hd2Zid3ns[EB1gXCnIFXNUFQwSUyNIDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJG5KUC9|VEOgZ4VtdHNuIFnDOVAhRSByLkCwNVMh|ryPLh?= NHe3bYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESzNVM1OCd-Mki0N|E{PDB:L3G+
NIH-3T3 MY\GeY5kfGmxbjDhd5NigQ>? MkjKNUBpeg>? NF\mNnJKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJGMyOTV4WTDteZRidnRiZYjwdoV{e2WmIHnuJI1wfXOnIF7JTE0{XDNiY3XscJMh[XO|ZYPz[YQh[XNicHjvd5Bpdy2DTFugcIV3\WxiYX\0[ZIhOSCqcjDifUB{[W6md3njbEBGVEmVQTygTWM2OCB;IECuNFAyPiEQvF2u Ml;mQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6MUmxNVYoRjJ2OEG5NVE3RC:jPh?=
NIH/3T3 M4SwZ2Z2dmO2aX;uJIF{e2G7 NEnQXFNKdmirYnn0bY9vKG:oIIfpcIQhfHmyZTDFUWw1N0GOSzDDNVE2PllibYX0ZY51KCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIF7JTE8{XDNiY3XscJMtKEmFNUCgQUAxNjByMU[g{txONg>? M1XUfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEOxN|QxLz5{OESzNVM1ODxxYU6=
BAF3 NY\1V2FSSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NE\pTIk4OiCqcoO= NIrOVmVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBSlMh[2WubIOgbIFz[m:{aX7nJGVOVDRvQVzLJIFnfGW{IEeyJIhzeyCkeTDTVmIhd3JiQ1PLPEBie3OjeTygTWM2OCB;IECuNFAzQSEQvF2u NHexclA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUK4PFk1OCd-MkmyPFg6PDB:L3G+
KARPAS299 NIPSO2FCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MnvGO|IhcHK| M2[0O2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iS1HSVGFUOjl7IHPlcIx{KGijcnLvdolv\yCQUF2tRWxMKGGodHXyJFczKGi{czDifUBUWkJib4KgR2NMQCCjc4PhfUwhUUN3MDC9JFAvODB|IN88UU4> NXHQOHhvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmyPFg6PDBpPkK5Nlg5QTRyPD;hQi=>
NIH-3T3 NFr1dIdHfW6ldHnvckBie3OjeR?= MmPXNUBpeg>? MkizTY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDTNVIxPllibYX0ZY51KGW6cILld5Nm\CCrbjDtc5V{\SCQSVitN3Q{KGOnbHzzJIF{e2W|c3XkJIF{KHCqb4PwbI8uSUyNIHzleoVtKGGodHXyJFEhcHJiYomgd4Fv\HerY3igSWxKW0FuIFnDOVAhRSByLkCwOFIh|ryPLh?= MlXoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6MUmxNVYoRjJ2OEG5NVE3RC:jPh?=
NIH/3T3 MofqSpVv[3Srb36gZZN{[Xl? M{PFO2lvcGmkaYTpc44hd2Zid3ns[EB1gXCnIFXNUFQwSUyNIGOxNlA3YSCvdYThcpQhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iTlnIM|NVOyClZXzsd{whUUN3MDC9JFAvODB2MjFOwG0v NEj3cW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESzNVM1OCd-Mki0N|E{PDB:L3G+
SU-DHL1 Mlq4RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MVm3NkBpenN? M2HZdmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU2WtSGhNOSClZXzsd{Bp[XKkb4LpcochVlCPLVHMT{Bi\nSncjC3NkBpenNiYomgV3JDKG:{IFPDT|gh[XO|YYmsJGlEPTBiPTCwMlAxPDlizszNMi=> MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTJ6OEm0NEc,Ojl{OEi5OFA9N2F-
NCI-H3122 M13ZeGFvfGmycn;sbYZmemG2aY\lJIF{e2G7 NH3rcJg4OiCqcoO= MofERY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCQQ1mtTFMyOjJiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JHNTSiCxcjDDR2s5KGG|c3H5MEBKSzVyIE2gNE4xODd6IN88UU4> MlvxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl{OEi5OFAoRjJ7Mki4PVQxRC:jPh?=
NIH-3T3 MoPTSpVv[3Srb36gZZN{[Xl? MYOxJIhz M1fwT2lvcGmkaYTpc44hd2ZiaIXtZY4hTU2OND3meZNm\CCDTFugUFEyPTKUIH31eIFvfCCneIDy[ZN{\WRiaX6gcY92e2ViTlnIMVNVOyClZXzsd{Bie3Onc4Pl[EBieyCyaH;zdIhwNUGOSzDs[ZZmdCCjZoTldkAyKGi{IHL5JJNidmS5aXPoJGVNUVODLDDJR|UxKD1iMD6wNFkh|ryPLh?= MnHRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6MUmxNVYoRjJ2OEG5NVE3RC:jPh?=
NIH/3T3 MWjGeY5kfGmxbjDhd5NigQ>? MnX4TY5pcWKrdHnvckBw\iC5aXzkJJR6eGViRV3MOE9CVEtiTEGxOVJTKG23dHHueEApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCQSVivN3Q{KGOnbHzzMEBKSzVyIE2gNE4xODlizszNMi=> NYLoWIIxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0N|E{PDBpPkK4OFMyOzRyPD;hQi=>
NIH-3T3 M1rPd2Z2dmO2aX;uJIF{e2G7 NW\zWmZEOSCqch?= MlrHTY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDHNVI3QUFibYX0ZY51KGW6cILld5Nm\CCrbjDtc5V{\SCQSVitN3Q{KGOnbHzzJIF{e2W|c3XkJIF{KHCqb4PwbI8uSUyNIHzleoVtKGGodHXyJFEhcHJiYomgd4Fv\HerY3igSWxKW0FuIFnDOVAhRSByLkCxOUDPxE1w NHPaTIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEixPVEyPid-MkS4NVkyOTZ:L3G+
NIH/3T3 MX;GeY5kfGmxbjDhd5NigQ>? NWjHO3I1UW6qaXLpeIlwdiCxZjD3bYxlKHS7cHWgSW1NPC:DTFugS|EzPjmDIH31eIFvfCBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDOTWgwO1R|IHPlcIx{NCCLQ{WwJF0hOC5yMUWg{txONg>? MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR|MUO0NEc,Ojh2M{GzOFA9N2F-
NIH-3T3 NF3wR3BHfW6ldHnvckBie3OjeR?= M3vQZVEhcHJ? M1jQR2lvcGmkaYTpc44hd2ZiaIXtZY4hTU2OND3meZNm\CCDTFugUFEyQT[PIH31eIFvfCCneIDy[ZN{\WRiaX6gcY92e2ViTlnIMVNVOyClZXzsd{Bie3Onc4Pl[EBieyCyaH;zdIhwNUGOSzDs[ZZmdCCjZoTldkAyKGi{IHL5JJNidmS5aXPoJGVNUVODLDDJR|UxKD1iMD6wNlEh|ryPLh?= M{HCOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEG5NVE3Lz5{NEixPVEyPjxxYU6=
NIH/3T3 MlfxSpVv[3Srb36gZZN{[Xl? NWm2PWdDUW6qaXLpeIlwdiCxZjD3bYxlKHS7cHWgSW1NPC:DTFugUFEyQT[PIH31eIFvfCBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDOTWgwO1R|IHPlcIx{NCCLQ{WwJF0hOC5yMkGg{txONg>? M3TmSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEOxN|QxLz5{OESzNVM1ODxxYU6=
NIH-3T3 MYTGeY5kfGmxbjDhd5NigQ>? M1rOV|EhcHJ? NYDZ[mxuUW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{AyOTVzVHnud{BufXSjboSg[ZhxemW|c3XkJIlvKG2xdYPlJG5KUC1|VEOgZ4VtdHNiYYPz[ZN{\WRiYYOgdIhwe3Cqbz3BUGshdGW4ZXygZYZ1\XJiMTDodkBjgSC|YX7ke4lkcCCHTFnTRUwhUUN3MDC9JFAvODN6IN88UU4> NV;zWWg4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4NVkyOTZpPkK0PFE6OTF4PD;hQi=>
NIH/3T3 Ml3TSpVv[3Srb36gZZN{[Xl? NV\IcIR4UW6qaXLpeIlwdiCxZjD3bYxlKHS7cHWgSW1NPC:DTFugNVE2OVSrboOgcZV1[W62IDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJG5KUC9|VEOgZ4VtdHNuIFnDOVAhRSByLkCzPEDPxE1w Mkn4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2M{GzOFAoRjJ6NEOxN|QxRC:jPh?=
BAF3 MYHBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? MWi3NkBpenN? M{HiTWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlHGN{Bk\WyuczDoZZJjd3KrbnegSW1NPC2DTFugUFEyQT[PIH31eIFvfCCjZoTldkA4OiCqcoOgZpkhW1KEIH;yJGNEUzhiYYPzZZktKEmFNUCgQUAxNjB2MkSg{txONg>? M2O4VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7Mki4PVQxLz5{OUK4PFk1ODxxYU6=
NIH-3T3 NUfoeIhjTnWwY4Tpc44h[XO|YYm= NECzTGYyKGi{ NVLYVGxrUW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{BIOTJyMmKgcZV1[W62IHX4dJJme3OnZDDpckBud3W|ZTDOTWguO1R|IHPlcIx{KGG|c3Xzd4VlKGG|IIDoc5NxcG9vQVzLJIxmfmWuIHHmeIVzKDFiaIKgZpkhe2GwZIfpZ4ghTUyLU1GsJGlEPTBiPTCwMlA4PyEQvF2u M2HqSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEG5NVE3Lz5{NEixPVEyPjxxYU6=
NIH/3T3 NWrqfVNvTnWwY4Tpc44h[XO|YYm= NIfGW2FKdmirYnn0bY9vKG:oIIfpcIQhfHmyZTDFUWw1N0GOSzDHNVIxOlJibYX0ZY51KCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIF7JTE8{XDNiY3XscJMtKEmFNUCgQUAxNjB5NzFOwG0v NH7ZfnY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESzNVM1OCd-Mki0N|E{PDB:L3G+
BAF3 MmrWRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? M4TuZVczKGi{cx?= MXjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDRkOgZ4VtdHNiaHHyZo9zcW6pIFXNUFQuSUyNIFexNlAzWiCvdYThcpQh[W[2ZYKgO|IhcHK|IHL5JHNTSiCxcjDDR2s5KGG|c3H5MEBKSzVyIE2gNE4zKM7:TT6= MmXDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl{OEi5OFAoRjJ7Mki4PVQxRC:jPh?=
BAF3 MorPRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MUi3NkBpenN? MWXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDRkOgZ4VtdHNiaHHyZo9zcW6pIFPEO|QuWk:VMTDHNlA{OlJibYX0ZY51KGGodHXyJFczKGi{czDifUBUWkJib4KgR2NMQCCjc4PhfUwhUUN3MDC9JFAvOjZ{IN88UU4> NVLqNJI1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmyPFg6PDBpPkK5Nlg5QTRyPD;hQi=>
HCC78 MYTBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? MWW3NkBpenN? NXz5dGNHSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR2M4QCClZXzsd{Bp[XKkb4LpcochW0yFM{TBNk1TV1NzIHHmeIVzKDd{IHjyd{BjgSCVUlKgc5IhS0ONODDhd5NigSxiSVO1NEA:KDBwM{W3JO69VS5? NXXHbJhoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmyPFg6PDBpPkK5Nlg5QTRyPD;hQi=>
SU-DHL1 Ml[4SpVv[3Srb36gZZN{[Xl? MoHsTY5pcWKrdHnvckBw\iCDTFugbY4hcHWvYX6gV3UuTEiOMTDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4hW1SDVEOgdIhwe3Cqb4L5cIF1cW:wIHH0JHk4ODVicnXzbYR2\SCjdDCyNEB1dyB6MDDuUUBi\nSncjCxJIhzKGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=> NXHP[nJFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmyPFg6PDBpPkK5Nlg5QTRyPD;hQi=>
SU-DHL1 M4DHbWZ2dmO2aX;uJIF{e2G7 NG\xVWRKdmirYnn0bY9vKG:oIFHMT{BqdiCqdX3hckBUXS2GSFyxJINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiCDa4SgdIhwe3Cqb4L5cIF1cW:wIHH0JHM1PzNicnXzbYR2\SCjdDCyNEB1dyB6MDDuUUBi\nSncjCxJIhzKGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=> MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTJ6OEm0NEc,Ojl{OEi5OFA9N2F-
SU-DHL1 NGn4[XVHfW6ldHnvckBie3OjeR?= NWTZdY4xUW6qaXLpeIlwdiCxZjDBUGsheGixc4Doc5J6dGG2aX;uJIF1KFlzMke4JJJme2mmdXWgbY4hcHWvYX6gV3UuTEiOMTDj[YxteyCjdDCyNEB1dyB6MDDuUUBi\nSncjCxJIhzKGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=> NUTtfpg5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmyPFg6PDBpPkK5Nlg5QTRyPD;hQi=>
SU-DHL1 NFXZeXhHfW6ldHnvckBie3OjeR?= MmDHTY5pcWKrdHnvckBw\iCDTFugbY4hcHWvYX6gV3UuTEiOMTDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4hTVKNIIDoc5NxcG:{eXzheIlwdiCjdDDUNlAzNy:\MkC0JJJme2mmdXXzJIF1KDJyIITvJFgxKG6PIHHmeIVzKDFiaIKgZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m| MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTJ6OEm0NEc,Ojl{OEi5OFA9N2F-
NCI-H3122 NW[4O5Z2TnWwY4Tpc44h[XO|YYm= M{TQU2lvcGmkaYTpc44hd2ZiQVzLJJBpd3OyaH;yfYxifGmxbjDheEB[OTJ5ODDy[ZNq\HWnIHnuJIh2dWGwIF7DTU1JOzF{MjDj[YxteyCjdDCyNEB1dyB6MDDuUUBi\nSncjCxJIhzKGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=> MlXOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl{OEi5OFAoRjJ7Mki4PVQxRC:jPh?=
NCI-H3122 Mme1SpVv[3Srb36gZZN{[Xl? NVO1OJd3UW6qaXLpeIlwdiCxZjDBUGshcW5iaIXtZY4hVkOLLVizNVIzKGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDTWGFVOyCyaH;zdIhwenmuYYTpc44h[XRiWUewOUBz\XOrZIXlJIF1KDJyIITvJFgxKG6PIHHmeIVzKDFiaIKgZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m| Mkm1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl{OEi5OFAoRjJ7Mki4PVQxRC:jPh?=
NCI-H3122 M1jBSWZ2dmO2aX;uJIF{e2G7 NEGyWZVKdmirYnn0bY9vKG:oIFHMT{BqdiCqdX3hckBPS0lvSEOxNlIh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIFHreEBxcG:|cHjvdplt[XSrb36gZZQhWzR5MzDy[ZNq\HWnIHH0JFIxKHSxIEiwJI5OKGGodHXyJFEhcHJiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{ NFfvcHU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUK4PFk1OCd-MkmyPFg6PDB:L3G+
NCI-H3122 NVjPW4pnTnWwY4Tpc44h[XO|YYm= NYnNb5VzUW6qaXLpeIlwdiCxZjDBUGshcW5iaIXtZY4hVkOLLVizNVIzKGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDFVmsheGixc4Doc5J6dGG2aX;uJIF1KFR{MEKvM3kzODRicnXzbYR2\XNiYYSgNlAhfG9iOECgcm0h[W[2ZYKgNUBpeiCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM> NIG4[WU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUK4PFk1OCd-MkmyPFg6PDB:L3G+
Assay
Methods Test Index PMID
Western blot p-ALK / ALK 29650534
In vivo In rats, PF-06463922 displays low plasma clearance, a moderate volume of distribution, a reasonable half-life, low propensity for p-glycoprotein 1-mediated efflux and a bioavailability of 100%. [1] In vivo, PF-06463922 shows cytoreductive antitumor efficacy in the NIH3T3 xenograft models expressing human CD74-ROS1 and Fig-ROS1 via inhibition in ROS1 phosphorylation and the downstream signaling molecules, as well as inhibition of the cell cycle protein Cyclin D1 in tumors. [2] In vivo, PF-06463922 also demonstrates marked antitumor activity in mice bearing tumor xenografts expressing EML4-ALK, EML4-ALK-L1196M, EML4-ALK-G1269A, EML4-ALK-G1202R or NPM-ALK. [3]

Protocol (from reference)

Solubility (25°C)

In vitro

DMSO 81 mg/mL warmed
(199.3 mM)
Water Insoluble
Ethanol '30 mg/mL warmed

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.

5mg/mL

Chemical Information

Molecular Weight 406.41
Formula

C21H19FN6O2

CAS No. 1454846-35-5
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC1C2=C(C=CC(=C2)F)C(=O)N(CC3=NN(C(=C3C4=CC(=C(N=C4)N)O1)C#N)C)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04979988 Recruiting Drug: Lortlatinib ALK-positive Non-small-cell Lung Cancer Pfizer August 2 2021 --
NCT03726333 Recruiting Drug: lorlatinib Advanced Cancers Pfizer January 14 2020 Phase 1
NCT03542305 Completed Drug: Lorlatinib Renal Impairment Pfizer August 23 2018 Phase 1
NCT03505554 Recruiting Drug: Lorlatinib Anaplastic Large Cell Lymphoma ALK-Positive University of Milano Bicocca|Pfizer October 10 2017 Phase 2
NCT03107988 Recruiting Drug: Lorlatinib|Drug: Cyclophosphamide|Drug: Topotecan Neuroblastoma New Approaches to Neuroblastoma Therapy Consortium|Pfizer|University of Southern California|Solving Kids'' Cancer US/EU|Children''s Neuroblastoma Cancer Foundation|The Band of Parents|The Evan Foundation|Wade''s Army|Ronan Thompson Foundation|The Catherine Elizabeth Blair Memorial Foundation|Cookies for Kids'' Cancer September 1 2017 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Frequently Asked Questions

Question 1:
Do you have any special suggestions for solution of S7536, Lorlatinib (PF-6463922) to be applied to mouse models?

Answer:
For S7536, we recommend 2% DMSO+30% PEG 300+ddH2O (up to 5mg/ml) for in vivo application.

Tags: buy Lorlatinib (PF-6463922) | Lorlatinib (PF-6463922) supplier | purchase Lorlatinib (PF-6463922) | Lorlatinib (PF-6463922) cost | Lorlatinib (PF-6463922) manufacturer | order Lorlatinib (PF-6463922) | Lorlatinib (PF-6463922) distributor